Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411626 · ClinicalTrials.gov registry record
Home Reported Outcomes in PNH
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 128
- Enrollment target
- 1
- Study location
NCT06411626 is a study of Paroxysmal Nocturnal Hemoglobinuria that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 128 participants, below the 256-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06411626, a study of Paroxysmal Nocturnal Hemoglobinuria, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-Related Quality of Life (HRQoL) experienced by PNH patients. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures, the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL among PNH patients, including those receiving orally administered iptacopan.
Conditions Studied
Interventions
- OTHER PNH-relevant therapies
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2026-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06411626
The ClinicalTrials.gov registry entry for NCT06411626 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (50% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 1 intervention - of which PNH-relevant therapies is the first listed.
NCT06411626 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06411626 about?
NCT06411626 is a clinical study titled "Home Reported Outcomes in PNH". The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-Related Quality of Life (HRQoL) experienced by PNH patients. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-rep...
What is the current status of trial NCT06411626?
This trial is currently recruiting. The enrollment target is 128 participants. The study started on 2024-06-11. Estimated completion is 2026-06-15.
What conditions does trial NCT06411626 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
What interventions are being tested in trial NCT06411626?
The interventions under investigation include: PNH-relevant therapies (OTHER).
Who is sponsoring clinical trial NCT06411626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06411626 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The International PNH Interest Group PNH Registry
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
Global PNH Patient Registry
RECRUITING
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
-
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.